

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Lassa virus diversity and feasibility for universal... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-134/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-134" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Lassa virus diversity and feasibility for universal prophylactic vaccine" />
    
            <meta name="og:title" content="F1000Research Article: Lassa virus diversity and feasibility for universal prophylactic vaccine.">
            <meta name="og:description" content="Read the latest article version by Igor S. Lukashevich, Slobodan Paessler, Juan Carlos de la Torre, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="18574">
            <meta name="article-id" content="16989">
            <meta name="dc.title" content="Lassa virus diversity and feasibility for universal prophylactic vaccine">
            <meta name="dc.description" content="Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO&rsquo;s TPP for an LASV vaccine.">
            <meta name="dc.subject" content="Lassa virus, Lassa fever, vaccine development ">
            <meta name="dc.creator" content="Lukashevich, Igor S.">
            <meta name="dc.creator" content="Paessler, Slobodan">
            <meta name="dc.creator" content="de la Torre, Juan Carlos">
            <meta name="dc.date" content="2019/01/31">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.16989.1">
            <meta name="dc.source" content="F1000Research 2019 8:134">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Lassa virus">
            <meta name="prism.keyword" content="Lassa fever">
            <meta name="prism.keyword" content="vaccine development ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/01/31">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="134">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.16989.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-134">
            <meta name="citation_title" content="Lassa virus diversity and feasibility for universal prophylactic vaccine">
            <meta name="citation_abstract" content="Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO&rsquo;s TPP for an LASV vaccine.">
            <meta name="citation_description" content="Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO&rsquo;s TPP for an LASV vaccine.">
            <meta name="citation_keywords" content="Lassa virus, Lassa fever, vaccine development ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Igor S. Lukashevich">
            <meta name="citation_author_institution" content="Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 40292, USA">
            <meta name="citation_author" content="Slobodan Paessler">
            <meta name="citation_author_institution" content="Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA">
            <meta name="citation_author" content="Juan Carlos de la Torre">
            <meta name="citation_author_institution" content="Department of Immunology and Microbiology IMM-6, The Scripps Research Institute, La Jolla, CA, 92037, USA">
            <meta name="citation_publication_date" content="2019/01/31">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="134">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.16989.1">
            <meta name="citation_firstpage" content="134">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-134/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-134.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=18574 /> <input type=hidden id=articleId name=articleId value=16989 /> <input type=hidden id=xmlUrl value="/articles/8-134/v1/xml"/> <input type=hidden id=xmlFileName value="-8-134-v1.xml"> <input type=hidden id=article_uuid value=02320d34-25fb-4399-bb6d-79bf4df0585b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Lassa virus diversity and feasibility for universal prophylactic vaccine"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.16989.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.16989.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-134"
  },
  "headline": "Lassa virus diversity and feasibility for universal prophylactic vaccine",
  "datePublished": "2019-01-31T12:15:46",
  "dateModified": "2019-01-31T12:15:46",
  "author": [
    {
      "@type": "Person",
      "name": "Igor S. Lukashevich"
    },    {
      "@type": "Person",
      "name": "Slobodan Paessler"
    },    {
      "@type": "Person",
      "name": "Juan Carlos de la Torre"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO&rsquo;s TPP for an LASV vaccine."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-134.html",
            "name": "Lassa virus diversity and feasibility for universal prophylactic vaccine"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Lassa virus diversity and feasibility for universal prophylactic vaccine </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=18574 data-id=16989 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16989.1" data-recommended="" data-doi="10.12688/f1000research.16989.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-134/v1/pdf?article_uuid=02320d34-25fb-4399-bb6d-79bf4df0585b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-16989-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-16989-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-16989-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lukashevich IS, Paessler S and de la Torre JC. Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):134 (<a class=new-orange href="https://doi.org/10.12688/f1000research.16989.1" target=_blank>https://doi.org/10.12688/f1000research.16989.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-16989-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=16989 id=track-article-signin-16989 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16989?target=/articles/8-134.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18574 /> <input name=articleId type=hidden value=16989 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Lassa virus diversity and feasibility for universal prophylactic vaccine</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:igor.lukashevich@louisville.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Igor S. Lukashevich</span></a><a href="https://orcid.org/0000-0001-6523-5116" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6523-5116</div><sup>1</sup>,&nbsp;</span><span class="">Slobodan Paessler<sup>2</sup>,&nbsp;</span><span class="">Juan Carlos de la Torre<sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:igor.lukashevich@louisville.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Igor S. Lukashevich</span></a><a href="http://orcid.org/0000-0001-6523-5116" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6523-5116</div><sup>1</sup>,&nbsp;</span><span class="">Slobodan Paessler<sup>2</sup>,&nbsp;</span><span class="">Juan Carlos de la Torre<sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 31 Jan 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.16989.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 40292, USA<br/> <sup>2</sup> Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA<br/> <sup>3</sup> Department of Immunology and Microbiology IMM-6, The Scripps Research Institute, La Jolla, CA, 92037, USA<br/> <p> <div class=margin-bottom> Igor S. Lukashevich <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Slobodan Paessler <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Juan Carlos de la Torre <br/> <span>Roles: </span> Data Curation, Visualization, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44951-43437></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44952-43438></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44953-43436></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, <i>Mastomys natalensis</i>, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Lassa virus, Lassa fever, vaccine development </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Igor S. Lukashevich (<a href="mailto:igor.lukashevich@louisville.edu">igor.lukashevich@louisville.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Igor S. Lukashevich </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was partially supported by grants R01AI093450 (ISL) and R56AI135770 (SP) from the National Institute of Allergy and Infectious Diseases. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Lukashevich IS <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lukashevich IS, Paessler S and de la Torre JC. Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):134 (<a href="https://doi.org/10.12688/f1000research.16989.1" target=_blank>https://doi.org/10.12688/f1000research.16989.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 31 Jan 2019, <b>8</b>(F1000 Faculty Rev):134 (<a href="https://doi.org/10.12688/f1000research.16989.1" target=_blank>https://doi.org/10.12688/f1000research.16989.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 31 Jan 2019, <b>8</b>(F1000 Faculty Rev):134 (<a href="https://doi.org/10.12688/f1000research.16989.1" target=_blank>https://doi.org/10.12688/f1000research.16989.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e186>Introduction</h2><p class="" id=d31732e189>Lassa virus (LASV) was originally isolated from a nurse (Lily Pinneo; strain LP) in 1969 during a nosocomial outbreak in a mission hospital in the city of Jos in north-central Nigeria<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Electron microscopy of LASV-infected Vero cells revealed morphological similarities with the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV)<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. Currently, LASV belongs to the Old World group (OW or LCMV-LASV serocomplex) of the genus <i>Mammarenavirus</i> in the <i>Arenaviridae</i> family<sup><a href="#ref-3">3</a></sup>.</p><p class="" id=d31732e216>Persistently infected <i>Mastomys natalensis</i> is the main source of natural LASV infection of humans<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Rodent-to-human transmission occurs by the inhalation of dust contaminated by the excreta of infected rodents, direct contact of abraded skin with contaminated material, or the ingestion of contaminated food<sup><a href="#ref-7">7</a></sup>. Clusters of infected <i>M</i>. <i>natalensis</i> are responsible for spatial distribution of Lassa fever (LF) cases in endemic areas<sup><a href="#ref-8">8</a>–<a href="#ref-11">11</a></sup>. LASV infection is confined predominantly to <i>M. natalensis</i> monophylogenic group A-I in West Africa<sup><a href="#ref-12">12</a></sup>, whereas other phylogroups from Central and Southern African regions have been associated with the non-pathogenic OW arenaviruses Mopeia (MOPV), Morogoro (MORV), Gairo (GAIV), and Luna (LUNV)<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. The detection of LASV in eastern Nigeria in <i>M. natalensis</i> from phylogroup A-II, which occupies a territory extending up to eastern Congo, underlines the potential of LASV to infect other genetically related host species and expand its geographic distribution<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. In addition, the isolation of LASV from <i>Mastomys erythroleucus</i> and <i>Hylomyscus pamfi</i> in Guinea and Nigeria, respectively, suggests that host-switching events potentially contribute to LASV geographic expansion<sup><a href="#ref-17">17</a>,<a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup>. LASV-endemic areas cover about 80% of Sierra Leone (SL) and Liberia, 50% of Guinea, 40% of Nigeria, 30% of each of Ivory Coast, Togo, and Benin, and 10% of Ghana with an at-risk population as high as 200 million people<sup><a href="#ref-20">20</a>,<a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. Moreover, West Africa is undergoing rapid demographic and environmental changes that are likely to increase LASV spillover events in coming decades<sup><a href="#ref-10">10</a></sup>. The estimated global burden of LF is the highest among viral hemorrhagic fevers with the exception of dengue fever<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d31732e309>Most LASV human infections are asymptomatic or cause mild flu-like illness, but about 20% can result in manifested illness, which can progress to severe multi-organ failure, hypovolemic sepsis-like shock, and death. The overall estimated mortality rate for “rural” LASV infections is 1% to 2%<sup><a href="#ref-25">25</a>–<a href="#ref-28">28</a></sup>. Among hospitalized patients and some vulnerable groups (women in late pregnancies, children under 5 years, and individuals with immune deficiencies), LF fatality can be 50% or higher.</p><p class="" id=d31732e319>LASV infection has been largely ignored as a public health threat<sup><a href="#ref-11">11</a>,<a href="#ref-29">29</a></sup>. However, during 2015–2016, historically high (59.6%) mortality among laboratory-confirmed LF cases was reported in Nigeria<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>, triggering the re-evaluation of LF risk for global health security<sup><a href="#ref-11">11</a>,<a href="#ref-32">32</a></sup>. In 2017, the World Health Organization (WHO) identified LASV as a top-priority pathogen for fast-track research and vaccine development<sup><a href="#ref-33">33</a></sup>. From January through the middle of April 2018, 1,849 suspected LF cases were reported across 21 states of Nigeria with 25.4% fatality among confirmed cases<sup><a href="#ref-34">34</a></sup>, prompting the WHO to declare a public health emergency<sup><a href="#ref-35">35</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e359>Lassa virus genetic diversity</h2><p class="" id=d31732e362>LASV has a bi-segmented single-strand negative-sense RNA genome<sup><a href="#ref-36">36</a></sup>. The large (L) RNA encodes for the L protein, an RNA-dependent RNA polymerase, and for the matrix Z protein. The small (S) RNA encodes for the nucleoprotein (NP) and enveloped glycoprotein precursor (GPC), which is processed in infected cells into stable signal peptide (SSP) and the mature GP1 (attachment) and GP2 (fusion) glycoproteins.</p><p class="" id=d31732e369>Molecular dating indicates that LASV originated in Nigeria about 1,000 years ago and gradually moved westwards<sup><a href="#ref-6">6</a>,<a href="#ref-37">37</a>–<a href="#ref-39">39</a></sup>. Initial phylogenetic analysis revealed that LASV sequences clustered geographically independently of a rodent or human source and formed four major phylogenetic lineages<sup><a href="#ref-40">40</a></sup>. Lineages I–III comprise LASV strains isolated in different geographic areas of Nigeria. The largest lineage, lineage IV, with the prototypic JOSIAH/SL/76/H (JOS) includes strains from Guinea, Liberia, and SL. Genetic analysis of clinical LF samples collected in 2008–2013 confirmed the existence of four major LASV lineages and provided additional evidence for high LASV genetic diversity, up to 25% and 32% for the S and L RNA segments, respectively<sup><a href="#ref-38">38</a>,<a href="#ref-41">41</a></sup>. A lineage V, which has a sister relationship with lineage IV, has been proposed for LASV isolates from Mali and Ivory Coast<sup><a href="#ref-39">39</a>,<a href="#ref-42">42</a></sup>. In addition, a Togo isolate with a mosaic genome structure (the L segment related to clade II and the S segment related to lineages I and IV) has been proposed to represent a separate lineage VI<sup><a href="#ref-43">43</a></sup>. No evidence for LASV recombination has been presented so far, and naturally occurring LASV reassortment seems to be a rare event, since only three reassortants were identified among 194 LASV RNA clinical samples<sup><a href="#ref-38">38</a></sup>. LASV geography-based clustering suggests multiple infections of individuals travelling across different LASV-endemic areas as the most likely explanation for the observed LASV reassortants<sup><a href="#ref-6">6</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e416>Lassa virus genetic diversity and differences in clinical manifestations of Lassa fever disease</h2><p class="" id=d31732e419>Most LASV animal studies have been carried out with JOS or JOS-related strains from the same lineage (IV). Accordingly, there is very limited knowledge about the pathogenicity of Nigerian strains in guinea pigs and non-human primates (NHPs), which poses an obstacle for LASV vaccine development<sup><a href="#ref-44">44</a></sup>. The LASV/JOS (lineage IV) and LASV/803213/74/H (lineage II) are highly pathogenic for strain 13 guinea pigs<sup><a href="#ref-45">45</a>–<a href="#ref-49">49</a></sup>. However, the prototypic LASV/LP (lineage I) does not cause fatal disease in these animals<sup><a href="#ref-48">48</a></sup>. LASV/GA391/NIG/77/H (lineage III) is lethal for outbred guinea pigs<sup><a href="#ref-50">50</a></sup>, whereas wild-type LASV/JOS kills only 30% to 40% of outbred guinea pigs<sup><a href="#ref-49">49</a></sup>. Notably, there is a poor correlation between the clinical outcome of LF in humans and the virulence of LASV in guinea pigs<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d31732e450>LASV/JOS is highly pathogenic in NHPs and reproduces major biological markers of fatal human LF cases<sup><a href="#ref-52">52</a>–<a href="#ref-54">54</a></sup>. However, a recent LASV/JOS-related isolate from a case of LF in Mali was less pathogenic in cynomolgus macaques than LASV strains from SL and Liberia<sup><a href="#ref-55">55</a></sup>. LASV/803213 (lineage II) is the only Nigerian strain tested in NHPs and caused fatal disease with predominant liver involvement in line with a recent clinical report<sup><a href="#ref-56">56</a></sup> and experimental arenavirus-induced liver pathology characterized by aborted hepatocyte proliferation and upregulation of Axl-1<sup><a href="#ref-57">57</a></sup>, an additional LASV receptor (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18574/bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure1.gif"><img alt="bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18574/bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure1.gif"></a><div class=caption><h3>Figure 1. Nigerian strain of LASV induces LF-like human hepatitis with biomarkers of pathological hepatocyte proliferation.</h3><p id=d31732e485>Infection of common marmosets with LASV/803213 (lineage II) induced fatal hepatitis clinically and histologically similar to hepatitis caused by LASV/JOS (lineage IV)<sup><a href="#ref-66">66</a></sup>. (<b>A</b>) LASV S RNA of strain 803213 was detected by using RNAscope <i>in situ</i> hybridization and amplification (Advanced Cell Diagnostics, Inc.). Positively stained brown spots in liver tissues of LASV-infected marmosets (but not in tissues of mock-infected animals, not shown) are indicated by arrows. (<b>B</b>,<b>C</b>) Staining for AXL (additional LASV cell receptor) and Ki67 (hepatocyte proliferation marker) was performed as previously described<sup><a href="#ref-57">57</a></sup>. Positively stained cells are indicated by arrows. Tissues of mock-infected marmosets were negatively stained on these markers (not shown). (<b>D</b>) Detection of cell cycling p21 gene expression in fatally infected marmosets versus non-fatal (vaccinated) survivors was measured by quantitative reverse transcription polymerase chain reaction.</p></div></div><p class="" id=d31732e516>Clinical studies in SL and Liberia during the 1970s and 1980s<sup><a href="#ref-1">1</a>,<a href="#ref-58">58</a>–<a href="#ref-60">60</a></sup> established fever, pharyngitis, retrosternal pain, and proteinuria as the best predictors of LF, whereas the best predictor of outcome was fever, sore throat, and vomiting. Elevated levels of aspartate aminotransferase (AST) in plasma and high viremia were strongly associated with death<sup><a href="#ref-25">25</a></sup>. A high aspartate AST/alanine aminotransferase (AST/ALT) ratio suggested substantial involvement of non-hepatic tissues in LF pathogenesis. Low or undetectable levels of pro-inflammatory chemokines interleukin-8 (IL-8) and interferon (IFN)-inducible protein 10 (IP-10) and elevated levels of tumor necrosis factor-alpha (TNF-α) receptors and IL-6 were associated with fatal LF<sup><a href="#ref-61">61</a></sup>. High IL-6 in plasma is considered a biological marker of fatal LF linked with liver pathological regeneration<sup><a href="#ref-52">52</a>,<a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. Likewise, low levels of IL-6, IL-10, CD40L, AST, ALT, alkaline phosphatase, and blood urea nitrogen in LF patients from SL correlated with survival. At the terminal stage, LF is characterized by severe pulmonary edema and acute respiratory distress, and signs of encephalopathy are observed with coma and seizures<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d31732e552>A retrospective study on a small cohort of patients with LF treated during 2012–2013 in Jos hospital, north-central Nigeria, confirmed fever, hemorrhagic manifestations, cough, proteinuria, and retrosternal pain as clinical predictors of LF<sup><a href="#ref-64">64</a></sup>. During the 2016 transmission season, patients with LF were predominantly from urban areas and fever was not a leading clinical sign, whereas bleeding diathesis, abdominal pain, and headache were present in more than 50% of confirmed cases<sup><a href="#ref-65">65</a></sup>. Recent studies on a larger cohort of patients with LF treated in Irrua Specialist Teaching Hospital (Edo State, Nigeria)<sup><a href="#ref-56">56</a></sup> revealed similarities and differences between LF in SL and Nigeria. Both groups of patients had liver pathology manifestations, but Nigerian patients often had a lower AST/ALT ratio consistent with hepatocyte involvement. In both groups, higher viral load strongly correlated with poor outcome<sup><a href="#ref-25">25</a>,<a href="#ref-65">65</a></sup>. However, in contrast to SL LF, sepsis-associated hypothermia rather than fever was a predictor of poor outcome in Nigerian patients<sup><a href="#ref-67">67</a></sup>. LF patients younger than 5 or older than 55 were the most likely to die<sup><a href="#ref-30">30</a>,<a href="#ref-56">56</a></sup>. Kidney pathology, manifested as high creatinine and urea blood levels, was one of the most notable clinical features of Nigerian LF<sup><a href="#ref-56">56</a></sup>. Analysis of 2017–2018 Nigerian LASV strains did not reveal differences in LASV genetic lineages or the epidemiology of the disease compared with previous years<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. The reason for the recent LF increase in Nigeria is not clear but is potentially related to changes in rodent reservoir or improvements in diagnostics and public awareness or both.</p><p class="" id=d31732e597>Sensorineural hearing loss (SNHL) seems to be a common feature of LASV infection in West Africa, and up to 80% of individuals who experienced deafness had LASV-specific antibodies versus 19% of matched controls<sup><a href="#ref-22">22</a>,<a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. In a murine model of SNHL, LASV isolates from fatal or non-lethal human cases affected cochlear hair cells and induced degeneration of the spiral ganglion cells of the auditory nerve<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. This model will provide valuable insights into the mechanisms of SNHL in humans. In NHP survivors, a recent study documented the presence of severe vascular lesions in inner ear tissues<sup><a href="#ref-73">73</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e624>Immunity to Lassa virus and correlates of protection against Lassa fever</h2><p class="" id=d31732e627>Studies involving LF survivors and validated animal models of LASV infection indicate that early and robust virus-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses are the best correlates of protection but that neutralizing antibodies appear too late after infection and at low titers<sup><a href="#ref-52">52</a>,<a href="#ref-54">54</a>,<a href="#ref-74">74</a>–<a href="#ref-78">78</a></sup>. Moreover, individuals who experienced subclinical or mild forms of LF are susceptible to re-infection with LASV but have long-term protection against LF disease<sup><a href="#ref-7">7</a>,<a href="#ref-75">75</a>,<a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. Notably, LF survivors from Guinea had strong memory CD4<sup>+</sup> T-cell responses against conserved epitopes in NP and GP2 from LASV/JOS and Nigerian LASV strains<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>. Nevertheless, potent LASV neutralizing monoclonal antibodies can be isolated from LF survivors, and these antibodies were protective in animal models of LF<sup><a href="#ref-83">83</a>,<a href="#ref-84">84</a></sup>. Consequently, a replication-competent and deeply attenuated vaccine capable of inducing the right combination of both cellular and humoral responses would be the preferred candidate.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e683>Feasibility of a pan-Lassa virus vaccine</h2><p class="" id=d31732e686>LASV genetic diversity is a great challenge for the design of a “universal” preventive LF vaccine. Only one of three predicted cross-reactive HLA-A2-restricted LASV-GPC CD8<sup>+</sup> T-cell epitopes is shared between LASV/JOS (lineage IV) and LASV/GA391 (lineage III), and CD8<sup>+</sup> T cells from JOS-immunized transgenic mice did not recognize GA391-derived GPC epitopes<sup><a href="#ref-85">85</a></sup>. However, studies with the vaccine candidate reassortant ML29, carrying the L RNA from MOPV and the S RNA from LASV/JOS encoding the major protective antigens NP and GPC<sup><a href="#ref-86">86</a></sup>, provided the first evidence supporting the feasibility of a pan-LASV vaccine. The expression of NP is an important feature of ML29 contributing to cross-protection<sup><a href="#ref-46">46</a>,<a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>, which is consistent with the observation that NP-specific CD8<sup>+</sup> T cells play a major role in virus control in mice infected with LCMV<sup><a href="#ref-89">89</a></sup>, and LF survivors had strong CD4<sup>+</sup> T-cell responses recognizing conserved and variable epitopes of the LASV NP<sup><a href="#ref-81">81</a></sup>. These findings suggest that anti-NP response at an early stage effectively controls infection and contributes to cross-protective immunity.</p><p class="" id=d31732e728>A single immunization with ML29 fully protected guinea pigs and marmosets against fatal disease caused by LASV/JOS (lineage IV) and Nigerian strain 803213 (lineage II)<sup><a href="#ref-46">46</a>,<a href="#ref-88">88</a></sup>. In Rhesus macaques, on day 28 after ML29 immunization, up to 13% of spleen cells secreted IFN-γ after stimulation with distantly related LCMV<sup><a href="#ref-87">87</a></sup>. LASV shares about 50% sequence homology with LCMV, including conserved NP and GPC T-cell epitopes<sup><a href="#ref-90">90</a></sup>. However, naïve macaques challenged with the WE strain of LCMV died from an LF-like disease, whereas all ML29-vaccinated primates, including simian immunodeficiency virus (SIV)-infected monkeys, were protected against fatal LF-like disease<sup><a href="#ref-88">88</a>,<a href="#ref-91">91</a>–<a href="#ref-93">93</a></sup>. These results indicate that ML29 is safe and immunogenic and induces broad T-cell-mediated cross-protective immunity. Among available LASV vaccine candidates, safety and immunogenicity in SIV-infected Rhesus macaques (a model of human HIV-1 infection) are unique features of ML29<sup><a href="#ref-92">92</a></sup>. In West Africa, LF-endemic areas (for example, Nigeria) also have high HIV seroprevalence, and it is important to determine whether vaccination could be safe in the context of HIV-1 infection.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e764>Do current vaccine candidates meet World Health Organization guidelines?</h2><p class="" id=d31732e767>In 2017, the WHO released the Target Product Profile (TPP) for an LASV vaccine<sup><a href="#ref-94">94</a></sup> and emphasized the preventive use of the vaccine as the highest priority. Optimal candidate vaccines should fulfill the following criteria: (i) WHO-acceptable safety/reactogenicity, (ii) an injectable single-dose regimen, (iii) high (≥70%) efficacy in preventing infection or disease caused by LASV lineages I to IV, and (iv) confers long-lasting (≥5 years’) protection. Several virus-vectored vaccine candidates based on vaccinia virus<sup><a href="#ref-50">50</a>,<a href="#ref-74">74</a>,<a href="#ref-95">95</a></sup>, recombinant vesicular stomatitis virus (rVSV)<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a></sup>, MOPV<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>, ML29<sup><a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>, yellow fever 17D<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>, and alphavirus replicons<sup><a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup> have been tested in proof-of-concept studies in NHPs (<a href="#T1">Table 1</a>). Among them, ML29 and rVSV/LASV-GPC have been recommended for accelerated vaccine development by international vaccine experts<sup><a href="#ref-104">104</a></sup>. ML29 exhibits unique features to meet WHO TPP criteria: (i) safety in all available animal models of LF, including immunocompromised NHPs<sup><a href="#ref-92">92</a></sup>; (ii) induction, after a single shot, of protective sterilizing T-cell responses against SL and Nigerian strains of LASV<sup><a href="#ref-46">46</a>,<a href="#ref-105">105</a></sup> responsible for the ongoing outbreak in Nigeria<sup><a href="#ref-68">68</a></sup>; (iii) genetic stability <i>in vivo</i> and <i>in vitro</i><sup><a href="#ref-106">106</a></sup>; (iv) efficacy in post-exposure applications<sup><a href="#ref-107">107</a></sup>; and (v) favorable thermostability. The low dose of ML29 (1 × 10<sup>3</sup> plaque-forming units) required for the induction of protective immunity makes this vaccine attractive for manufacturers. This dose is in the range of the natural infection dose during rodent-to-human transmission<sup><a href="#ref-7">7</a></sup> and presents LASV NP- and CPC-derived epitopes to the major histocompatibility complex (MHC) molecules in the most effective way to induce robust cross-protective T-cell responses<sup><a href="#ref-46">46</a>,<a href="#ref-87">87</a>,<a href="#ref-88">88</a>,<a href="#ref-105">105</a></sup>. Depletion of CD8<sup>+</sup> T cells in ML29-immunized animals completely abolished protection, whereas CD4<sup>+</sup> T cells had partial effect<sup><a href="#ref-108">108</a></sup>. A recombinant ML29 (rML29) has recently been rescued from cDNA clones (<a href="#f2">Figure 2</a>). Arenavirus tri-segmented (r3) technology<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup> would allow for the generation of r3ML29 expressing additional LASV antigens to expand the cross-protection range of ML29-based LASV vaccines (for example, expressing GPC and NP antigens from distantly related lineage I, LASV/LP).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Advanced LASV vaccine candidates tested in “proof-of-concept” efficacy trials in NHPs.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d31732e909 class=n-a></a><thead><a name=d31732e911 class=n-a></a><tr><a name=d31732e913 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e915 class=n-a></a>Vaccine candidate</th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e918 class=n-a></a>LASV vaccine antigen formulation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e921 class=n-a></a>Vaccine regimen</th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e924 class=n-a></a>Efficacy against<br class=br>LASV/JOS<sup><a href="#note-1">a</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e932 class=n-a></a>Efficacy against<br class=br>LASV/NIG<sup><a href="#note-2">b</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e941 class=n-a></a>Viremia after challenge<sup><a href="#note-3">c</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e947 class=n-a></a>Correlates of protection</th><th align=left colspan=1 rowspan=1 valign=top><a name=d31732e950 class=n-a></a>Ref</th></tr></thead><tbody><a name=d31732e955 class=n-a></a><tr><a name=d31732e957 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e959 class=n-a></a>Recombinant vaccinia virus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e962 class=n-a></a>GPC (JOS)<br class=br>NP<br class=br>GPC&amp;NP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e969 class=n-a></a>Single vaccination, at four sites, total 1x10<sup>9</sup> PFU, ID</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e975 class=n-a></a>88%<br class=br>20%<br class=br>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e982 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e986 class=n-a></a>Low–moderate<br class=br>High<br class=br>~LD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e993 class=n-a></a>CMI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e996 class=n-a></a><sup><a href="#ref-50">50</a>,<a href="#ref-74">74</a>,<a href="#ref-95">95</a>,<a href="#ref-109">109</a></sup></td></tr><tr><a name=d31732e1011 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1013 class=n-a></a>Reassortant MOPV/LASV, ML29</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1016 class=n-a></a>GPC&amp;NP (JOS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1019 class=n-a></a>One dose, 1x10<sup>3</sup> PFU, SC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1025 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1028 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1032 class=n-a></a>&lt;LD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1035 class=n-a></a>Sterilizing CMI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1038 class=n-a></a><sup><a href="#ref-46">46</a>,<a href="#ref-87">87</a>,<a href="#ref-92">92</a>,<a href="#ref-105">105</a>–<a href="#ref-107">107</a></sup></td></tr><tr><a name=d31732e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1058 class=n-a></a>rVSVΔG/LVGPC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1061 class=n-a></a>GPC (JOS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1064 class=n-a></a>One dose, 1–6x10<sup>7</sup> PFU, IM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1070 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1073 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1077 class=n-a></a>Low, transient</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1080 class=n-a></a>nAbs? CMI?</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1083 class=n-a></a><sup><a href="#ref-48">48</a>,<a href="#ref-97">97</a></sup></td></tr><tr><a name=d31732e1092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1094 class=n-a></a>YF17D/LASV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1097 class=n-a></a>GPC (JOS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1100 class=n-a></a>Two doses, 1x10<sup>7</sup> FFU, SC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1106 class=n-a></a>20%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1109 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1113 class=n-a></a>Moderate–high</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1116 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1119 class=n-a></a><sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>, Lukashevich,<br class=br>unpublished</td></tr><tr><a name=d31732e1131 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1133 class=n-a></a>VEEV-TC83 RNA replicon particles</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1136 class=n-a></a>GPC (JOS&amp;LP)<sup><a href="#note-4">d</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1142 class=n-a></a>Two doses, 1x10<sup>7</sup>, SC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1148 class=n-a></a>80%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1151 class=n-a></a>20%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1155 class=n-a></a>Moderate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1158 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1161 class=n-a></a><sup><a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup>, Lukashevich,<br class=br>unpublished</td></tr><tr><a name=d31732e1174 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1176 class=n-a></a>MOPEVAC<sub>LASV</sub></td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1181 class=n-a></a>GPC (JOS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1184 class=n-a></a>One dose, 6x10<sup>6</sup> PFU/dose, SC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1190 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1193 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1197 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1200 class=n-a></a>nAbs, CMI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1203 class=n-a></a><sup><a href="#ref-99">99</a></sup></td></tr><tr><a name=d31732e1209 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1211 class=n-a></a>DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1214 class=n-a></a>GPC (JOS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1217 class=n-a></a>Two immunizations, 20 mg DNA at four sites, ID electroporation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1220 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1223 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1227 class=n-a></a>ND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1230 class=n-a></a>nAbs?</td><td align=left colspan=1 rowspan=1 valign=top><a name=d31732e1233 class=n-a></a><sup><a href="#ref-110">110</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=note-1 class=n-a></a><p id=d31732e1245> <sup>a</sup> Challenge dose: 1x10<sup>3</sup>–1x10<sup>4</sup> PFU of LASV/JOS (lineage IV), route of inoculation: SC or IM. LASV-Z32 (Liberia, lineage IV) was also used in vaccination/challenge experiments with rVSVΔG/LVGPC<sup><a href="#ref-47">47</a></sup>.</p></div><div class=footnote><a name=note-2 class=n-a></a><p id=d31732e1264> <sup>b</sup> Nigerian strain of 803213 (lineage II) was used in vaccination/challenge experiments with ML29 vaccine in marmosets. This strain causes fatal disease mimicking LF human hepatitis and features of arenaviral hepatitis in a murine model (<a href="#f1">Figure 1</a>).</p></div><div class=footnote><a name=note-3 class=n-a></a><p id=d31732e1276> <sup>c</sup> Low–moderate, 10<sup>3</sup>–10<sup>4</sup> PFU/mL; high, &gt;10<sup>4</sup> PFU/mL.</p></div><div class=footnote><a name=note-4 class=n-a></a><p id=d31732e1294> <sup>d</sup> The genetic backbone of VEEV TC-83 vaccine was used to design bicistronic RNA replicons encoding wild-type LASV-GPC (JOS or LP) and C-terminally deleted, non-cleavable modified glycoproteins fused with fibritin. Bicistronic replicons were encapsidated into virus-like-particles using VEEV capsid and glycoproteins provided in <i>trans</i><sup><a href="#ref-94">94</a></sup>.</p></div><div class=footnote><a name=d31732e1307 class=n-a></a><p id=d31732e1309> Abbreviations: CMI, cell-mediated immunity; FFU, fluorescent forming units; GPC, glycoprotein; GPC&amp;NP, simultaneous expression of NP and GPC in the same vector; ID, intradermal; IM, intramuscular; LASV, Lassa virus; LD, limit of detection; nAbs, neutralizing antibody responses; ND, not done; NHP, non-human primate; NP, nucleoprotein; PFU, plaque-forming unit; SC, subcutaneous.</p></div></div></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18574/bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure2.gif"><img alt="bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18574/bae6db5b-2c33-4b1a-9e6e-519ff5e0a079_figure2.gif"></a><div class=caption><h3>Figure 2. Generation of r3ML29.</h3><p id=d31732e1325>BHK-21 cells were transfected with pol-II expression plasmids for ML29 L and NP, required to support viral replication and transcription, together with plasmids that direct pol-I-mediated intracellular synthesis of L, and recombinant S1 and S2 RNA genome species. Six days later, tissue culture supernatants were collected and used to infect Vero cells to amplify the rescued r3ML29 that were plaque-purified and scaled up to generate viral stocks. (<b>A</b>) Genome organization of r3ML29/eGFP. (<b>B</b>) r3ML29/EGFP grows to high titers in Vero cells. Cells were infected (multiplicity of infection = 0.1) and virus titers in tissue culture were determined at the indicated times. The rML29 reverse genetics is an advanced vaccine platform to further improve the safety and immunogenicity of Lassa virus vaccine candidates. FFU, focus-forming units; GFP, green fluorescent protein; GPC, glycoprotein precursor; h.p.i., hours post-infection; LoD, limit of detection; NP, nucleoprotein; TCS, tissue culture supernatant.</p></div></div><p class="" id=d31732e1338>Reverse genetics has also been used to generate more attenuated MOPV by disrupting the 3'–5' exonuclease (Exo) domain of NP required for its anti-IFN activity<sup><a href="#ref-99">99</a></sup>. LASV/JOS GPC gene was cloned and expressed in MOPVAC<sub>ExoN6b</sub>, and a single immunization of MOPEVAC<sub>LASV</sub> fully protected NHPs from a homologous lethal challenge. However, disrupting NP Exo resulted in about 100-fold yield reduction of MOPEVAC<sub>LASV</sub> production in cultured cells<sup><a href="#ref-99">99</a></sup>, which combined with a required high dose (6 × 10<sup>6</sup> focus-forming units) will pose obstacles for manufacturing and developing this vaccine candidate.</p><p class="" id=d31732e1363>A single injection of the rVSV/LASV-GPC experimental vaccine where LASV-GPC was substituted for VSV-G fully protected guinea pigs and NHPs against LASV strains from the same lineage<sup><a href="#ref-48">48</a>,<a href="#ref-97">97</a></sup>. The rVSVΔG/LASV-GPC immunization did not induce detectable levels of T-cell responses before challenge, and low humoral responses in IgG enzyme-linked immunosorbent assay were found in three out of four vaccinated animals. After LASV challenge, neutralizing antibodies were detected in all four macaques<sup><a href="#ref-97">97</a></sup>.</p><p class="" id=d31732e1377>The Coalition for Epidemic Preparedness Innovations (CEPI) (<a target=xrefwindow href="http://cepi.net" id=d31732e1379>http://cepi.net</a>) was recently created as a non-profit organization to accelerate vaccine development against emerging epidemic infections when the commercial market is insufficient to justify private investment<sup><a href="#ref-113">113</a></sup>. CEPI supports the development of vaccine candidates from the late pre-clinical stage to phase II and stockpiling for emergency use. The CEPI initiative has been widely welcomed and supported by multiple governments, philanthropic organizations, and industrial partners. The development of LASV vaccines was included in an aggressive CEPI Business Plan (2017–2021) with the goal of testing safety and efficacy in human phase IIa/b trials and stockpiling. One of the first LASV vaccine candidates supported by CEPI is being developed by Themis Bioscience and is based on recombinant measles vaccine technology from Institute Pasteur (<a target=xrefwindow href="https://www.themisbio.com/" id=d31732e1386>www.themisbio.com</a>). The measles virus vector-based vaccine platform looks promising for human infections with antibody-based protection<sup><a href="#ref-114">114</a></sup>. However, there are no peer-reviewed pre-clinical data to support the application of this platform for the development of an LF vaccine with a predominant T-cell-mediated mechanism of protection. Pre-existing anti-vector immunity, as it might affect the outcome of clinical studies, has to be addressed for this approach. CEPI is also supporting a DNA-based vaccine against LASV<sup><a href="#ref-115">115</a></sup>, which raises feasibility questions. There is no DNA preventive vaccine licensed for human use. Scientific interest on DNA vaccine endeavors has decreased because of difficulties in improving DNA immunogenicity<sup><a href="#ref-116">116</a></sup>. Further advancement of plasmid formulations and delivery will be required to see the first licensed DNA vaccine for people “in the next 20 years”<sup><a href="#ref-117">117</a></sup>. LASV infection is not an easy target for DNA vaccination since both antigens—NP and GPC—have to be included in the vaccine formulation<sup><a href="#ref-118">118</a></sup>. Electroporation of LASV-GPC DNA induced modest levels of neutralizing antibodies, providing additional evidence that T-cell responses played a major role in the protection of NHPs<sup><a href="#ref-110">110</a></sup>.</p><p class="" id=d31732e1415>Two additional CEPI awards were announced to support rVSV-based LASV vaccines. The rVSVΔG/LASV-GPC is based on the same platform applied to design the rVSVΔG/ZEBOV-GP vaccine, which was tested in a ring vaccination trial in Guinea<sup><a href="#ref-119">119</a>,<a href="#ref-120">120</a></sup> and which appeared to provide some protection, but its efficacy remains to be determined<sup><a href="#ref-121">121</a></sup>. Clinical studies documented side effects associated with the rVSVΔG-based vaccine, including post-vaccination arthritis, detection of vector RNA in blood, and infectious vaccine virus in the skin of vaccinated individuals<sup><a href="#ref-122">122</a>,<a href="#ref-123">123</a></sup>. Animal studies were not always in line with Ebola virus (EBOV) vaccine clinical trials, suggesting that immune correlates of protection are not universal and depend on vaccine platform, vaccine regimen, host genetics, pre-existing immunity, immunization schedule, and challenge protocol<sup><a href="#ref-124">124</a></sup>. This lesson from EBOV vaccine development is applicable to LASV, since dependence on vaccine platform and vaccine recipients has been documented<sup><a href="#ref-48">48</a>,<a href="#ref-50">50</a>,<a href="#ref-74">74</a>,<a href="#ref-102">102</a>,<a href="#ref-109">109</a></sup> (<a href="#T1">Table 1</a>). The second rVSV-based LASV vaccine candidate supported by CEPI is based on the VesiculoVax platform licensed by Profectus BioSciences. This platform was developed to further improve the safety of the rVSV vector by N gene translocation and truncation of VSV-G cytoplasmic tail (CT1). The attenuated rVSV-N4CT1 vector was immunogenic in NHPs and induced only a mild inflammatory response after intra-thalamic inoculation<sup><a href="#ref-125">125</a></sup>. This vector was used to generate experimental vaccines expressing single or multiple GPs that protected NHPs against EBOV and MARV challenges<sup><a href="#ref-126">126</a>–<a href="#ref-128">128</a></sup>, but there are no peer-reviewed pre-clinical data in support of the LASV vaccine based on the VesiculoVax platform. Likewise, CEPI supported pre-clinical development of the LASV-GPC-based vaccine vectored by non-replicating simian adenovirus ChAdOx1<sup><a href="#ref-129">129</a></sup>, but there is no evidence supporting the suitability of this platform to control LF on the basis of natural history of the disease and mechanisms of protective immunity<sup><a href="#ref-54">54</a>,<a href="#ref-74">74</a>,<a href="#ref-77">77</a>,<a href="#ref-130">130</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d31732e1491>Conclusions</h2><p class="" id=d31732e1494>Protection against Nigerian strains of LASV is a critical requirement for LASV vaccines<sup><a href="#ref-94">94</a></sup>. WHO pre-qualification requirements raise a high bar for vaccine developers and emphasize the WHO-preferred vaccine candidate as a preventive and cost-effective measure for the general population in endemic areas. Among currently available LASV vaccine candidates, only ML29 has been shown to protect against LASV strains from lineage II, which is responsible for the current LF outbreak in Nigeria<sup><a href="#ref-46">46</a>,<a href="#ref-68">68</a>,<a href="#ref-88">88</a></sup>.</p><p class="" id=d31732e1511>The “stockpiling” for emergency use is a workable concept for infections with unknown epidemiology and unpredictable outbreaks (for example, EBOV, Nipah, and severe acute respiratory syndrome) but poorly justifiable in the case of LASV, for which endemic areas are well defined and natural reservoir and key routes of human transmission are known. Population-based vaccination is the most effective option to control LF in endemic areas. The successful story of Candid #1, a live-attenuated vaccine against Argentine hemorrhagic fever<sup><a href="#ref-131">131</a></sup>, provides a guideline for LASV vaccine clinical development. Because of the high LASV genetic diversity, multicenter trials in several endemic areas (countries) would probably be required to evaluate the cross-protective efficacy of vaccine candidates. Pre-existing LASV immunity potentially affects vaccine dose-dependent responses, and appropriate efforts must be applied during human trial design to correctly assess vaccine immunogenicity. Rooted research collaborations and capacity building will be crucial for anticipating multicenter immunogenicity and efficacy trials in West Africa<sup><a href="#ref-132">132</a>,<a href="#ref-133">133</a></sup>.</p><p class="" id=d31732e1525>The WHO-preferred LASV vaccine should cover both adult and pediatric populations. It seems reasonable to plan pediatric studies after the successful completion of phase II trials in adults. Pediatric studies are subject to special provisions of the clinical trial regulations. However, it should be noted that replication-competent US Food and Drug Administration (FDA)-approved pediatric vaccines include reassortant influenza (FluMist, MedImmune) and human-bovine rotavirus (RotaTeq, Merck) vaccines. The safety and efficacy of these vaccines in children and infants indicate that reassortant vaccine platforms are well suited for the pediatric population. The ML29 LASV vaccine can be safe in children as well, since safety and immunogenicity in SIV-infected Rhesus macaques have already been documented<sup><a href="#ref-92">92</a></sup>.</p><p class="" id=d31732e1532>The FDA does not recommend replication-competent vaccines for pregnant women, an LF risk group with a high fatality rate, especially in the third trimester of pregnancy. Replication-deficient Modified Vaccinia Ankara vector generating LASV-like particles (MVA-VLP, GeoVax Labs) or inactivated recombinant vaccine candidate expressing LASV-GPC in rabies vaccine vector (LASSARAB)<sup><a href="#ref-134">134</a></sup> can be potentially considered as vaccine candidates for this group of risk. Currently, these vaccines are in very early pre-clinical steps of development.</p><p class="" id=d31732e1540>The CEPI LASV vaccine portfolio is based on different features of vaccine platforms rather than the natural history of the disease and rational vaccine design. The head-to-head comparison of LASV vaccine candidates in validated NHP models under supervision of unbiased internationally recognized experts to assess cross-protective breadth seems a very reasonable step before going into expensive clinical phase II trials<sup><a href="#ref-93">93</a></sup>. This comparison, combined with phase I safety data, will provide very valuable information for further clinical development to target different groups at risk in endemic areas of West Africa.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d31732e1 class=n-a></a><h2 class=main-title id=d32103>Grant information</h2><p>This work was partially supported by grants R01AI093450 (ISL) and R56AI135770 (SP) from the National Institute of Allergy and Infectious Diseases.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d31732e1551 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d32564>References</h2><div class="section ref-list"><a name=d31732e1551 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d31732e1558 class=n-a></a>Frame JD, Baldwin JM Jr, Gocke DJ, <i> et al.</i>: Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. <i>Am J Trop Med Hyg.</i> 1970; <b>19</b>(4): 670–6. <a target=xrefwindow id=d31732e1569 href="http://www.ncbi.nlm.nih.gov/pubmed/4246571">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1572 href="https://doi.org/10.4269/ajtmh.1970.19.670">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d31732e1581 class=n-a></a>Troup JM, White HA, Fom AL, <i> et al.</i>: An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. <i>Am J Trop Med Hyg.</i> 1970; <b>19</b>(4): 695–6. <a target=xrefwindow id=d31732e1592 href="http://www.ncbi.nlm.nih.gov/pubmed/4987549">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1595 href="https://doi.org/10.4269/ajtmh.1970.19.695">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d31732e1604 class=n-a></a>Radoshitzky SR, Bào Y, Buchmeier MJ, <i> et al.</i>: Past, present, and future of arenavirus taxonomy. <i>Arch Virol.</i> 2015; <b>160</b>(7): 1851–74. <a target=xrefwindow id=d31732e1615 href="http://www.ncbi.nlm.nih.gov/pubmed/25935216">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1618 href="https://doi.org/10.1007/s00705-015-2418-y">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d31732e1627 class=n-a></a>Speir RW, Wood O, Liebhaber H, <i> et al.</i>: Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus. <i>Am J Trop Med Hyg.</i> 1970; <b>19</b>(4): 692–4. <a target=xrefwindow id=d31732e1638 href="http://www.ncbi.nlm.nih.gov/pubmed/4987548">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1641 href="https://doi.org/10.4269/ajtmh.1970.19.692">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d31732e1650 class=n-a></a>Monath TP, Newhouse VF, Kemp GE, <i> et al.</i>: Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. <i>Science.</i> 1974; <b>185</b>(4147): 263–5. <a target=xrefwindow id=d31732e1661 href="http://www.ncbi.nlm.nih.gov/pubmed/4833828">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1664 href="https://doi.org/10.1126/science.185.4147.263">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d31732e1674 class=n-a></a>Lalis A, Wirth T: Mice and Men: an Evolutionary History of Lassa Fever. <i>Biodivers Evol.</i> 2018; 189–212. <a target=xrefwindow id=d31732e1679 href="https://doi.org/10.1016/B978-1-78548-277-9.50011-5">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d31732e1688 class=n-a></a>McCormick JB: Epidemiology and control of Lassa fever. <i>Curr Top Microbiol Immunol.</i> 1987; <b>134</b>: 69–78. <a target=xrefwindow id=d31732e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/3581899">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1699 href="https://doi.org/10.1007/978-3-642-71726-0_3">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d31732e1708 class=n-a></a>Demby AH, Inapogui A, Kargbo K, <i> et al.</i>: Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. <i>Vector Borne Zoonotic Dis.</i> 2001; <b>1</b>(4): 283–97. <a target=xrefwindow id=d31732e1719 href="http://www.ncbi.nlm.nih.gov/pubmed/12653128">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1722 href="https://doi.org/10.1089/15303660160025912">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726172043"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1731 class=n-a></a>Fichet-Calvet E, Ölschläger S, Strecker T, <i> et al.</i>: Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea. <i>Sci Rep.</i> 2016; <b>6</b>: 21977. <a target=xrefwindow id=d31732e1742 href="http://www.ncbi.nlm.nih.gov/pubmed/26911443">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1745 href="https://doi.org/10.1038/srep21977">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4766397">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726172043">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728531043"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1762 class=n-a></a>Redding DW, Moses LM, Cunningham AA, <i> et al.</i>: Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: A case study of Lassa fever. <i>Methods Ecol Evol.</i> 2016; <b>7</b>(6): 646–55. <a target=xrefwindow id=d31732e1773 href="https://doi.org/10.1111/2041-210X.12549">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728531043">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731120628"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1786 class=n-a></a>Gibb R, Moses LM, Redding DW, <i> et al.</i>: Understanding the cryptic nature of Lassa fever in West Africa. <i>Pathog Glob Health.</i> 2017; <b>111</b>(6): 276–88. <a target=xrefwindow id=d31732e1797 href="http://www.ncbi.nlm.nih.gov/pubmed/28875769">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1800 href="https://doi.org/10.1080/20477724.2017.1369643">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1804 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5694855">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731120628">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727194381"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1818 class=n-a></a>Gryseels S, Baird SJ, Borremans B, <i> et al.</i>: When Viruses Don't Go Viral: The Importance of Host Phylogeographic Structure in the Spatial Spread of Arenaviruses. <i>PLoS Pathog.</i> 2017; <b>13</b>(1): e1006073. <a target=xrefwindow id=d31732e1829 href="http://www.ncbi.nlm.nih.gov/pubmed/28076397">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1832 href="https://doi.org/10.1371/journal.ppat.1006073">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1836 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5226678">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727194381">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d31732e1849 class=n-a></a>Wulff H, McIntosh BM, Hamner DB, <i> et al.</i>: Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. <i>Bull World Health Organ.</i> 1977; <b>55</b>(4): 441–4. <a target=xrefwindow id=d31732e1860 href="http://www.ncbi.nlm.nih.gov/pubmed/304387">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1863 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2366678">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d31732e1872 class=n-a></a>Günther S, Hoofd G, Charrel R, <i> et al.</i>: Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. <i>Emerg Infect Dis.</i> 2009; <b>15</b>(12): 2008–12. <a target=xrefwindow id=d31732e1883 href="http://www.ncbi.nlm.nih.gov/pubmed/19961688">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1886 href="https://doi.org/10.3201/eid1512.090864">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1890 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3044542">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d31732e1899 class=n-a></a>Ishii A, Thomas Y, Moonga L, <i> et al.</i>: Novel arenavirus, Zambia. <i>Emerg Infect Dis.</i> 2011; <b>17</b>(10): 1921–4. <a target=xrefwindow id=d31732e1910 href="http://www.ncbi.nlm.nih.gov/pubmed/22000372">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1913 href="https://doi.org/10.3201/eid1710.10452">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1917 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3310648">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d31732e1926 class=n-a></a>Gryseels S, Rieger T, Oestereich L, <i> et al.</i>: Gairo virus, a novel arenavirus of the widespread <i>Mastomys natalensis</i>: Genetically divergent, but ecologically similar to Lassa and Morogoro viruses. <i>Virology.</i> 2015; <b>476</b>: 249–56. <a target=xrefwindow id=d31732e1940 href="http://www.ncbi.nlm.nih.gov/pubmed/25559385">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1944 href="https://doi.org/10.1016/j.virol.2014.12.011">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726910880"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1953 class=n-a></a>Olayemi A, Obadare A, Oyeyiola A, <i> et al.</i>: Arenavirus Diversity and Phylogeography of <i>Mastomys natalensis</i> Rodents, Nigeria. <i>Emerg Infect Dis.</i> 2016; <b>22</b>(4): 694–7. <a target=xrefwindow id=d31732e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/26982388">PubMed Abstract </a> | <a target=xrefwindow id=d31732e1971 href="https://doi.org/10.3201/eid2204.150155">Publisher Full Text </a> | <a target=xrefwindow id=d31732e1974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4806934">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726910880">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733637831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e1988 class=n-a></a>Olayemi A, Oyeyiola A, Obadare A, <i> et al.</i>: Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. <i>Parasit Vectors.</i> 2018; <b>11</b>(1): 416. <a target=xrefwindow id=d31732e1999 href="http://www.ncbi.nlm.nih.gov/pubmed/30005641">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2002 href="https://doi.org/10.1186/s13071-018-2991-5">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2006 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6045851">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733637831">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d31732e2019 class=n-a></a>Irwin NR, Bayerlová M, Missa O, <i> et al.</i>: Complex patterns of host switching in New World arenaviruses. <i>Mol Ecol.</i> 2012; <b>21</b>(16): 4137–50. <a target=xrefwindow id=d31732e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/22693963">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2033 href="https://doi.org/10.1111/j.1365-294X.2012.05663.x">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d31732e2042 class=n-a></a>Sogoba N, Feldmann H, Safronetz D: Lassa fever in West Africa: evidence for an expanded region of endemicity. <i>Zoonoses Public Health.</i> 2012; <b>59 Suppl 2</b>: 43–7. <a target=xrefwindow id=d31732e2050 href="http://www.ncbi.nlm.nih.gov/pubmed/22958249">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2053 href="https://doi.org/10.1111/j.1863-2378.2012.01469.x">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726327614"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2062 class=n-a></a>Olayemi A, Cadar D, Magassouba NF, <i> et al.</i>: New Hosts of The Lassa Virus. <i>Sci Rep.</i> 2016; <b>6</b>: 25280. <a target=xrefwindow id=d31732e2073 href="http://www.ncbi.nlm.nih.gov/pubmed/27140942">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2076 href="https://doi.org/10.1038/srep25280">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2080 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4853722">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726327614">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d31732e2093 class=n-a></a>Richmond JK, Baglole DJ: Lassa fever: epidemiology, clinical features, and social consequences. <i>BMJ.</i> 2003; <b>327</b>(7426): 1271–5. <a target=xrefwindow id=d31732e2101 href="http://www.ncbi.nlm.nih.gov/pubmed/14644972">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2104 href="https://doi.org/10.1136/bmj.327.7426.1271">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/286250">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d31732e2116 class=n-a></a>Fichet-Calvet E, Rogers DJ: Risk Maps of Lassa Fever in West Africa. <i>PLoS Negl Trop Dis.</i> 2009; <b>3</b>(3): e388. <a target=xrefwindow id=d31732e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/19255625">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2127 href="https://doi.org/10.1371/journal.pntd.0000388">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2130 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2644764">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d31732e2140 class=n-a></a>Falzarano D, Feldmann H: Vaccines for viral hemorrhagic fevers--progress and shortcomings. <i>Curr Opin Virol.</i> 2013; <b>3</b>(3): 343–51. <a target=xrefwindow id=d31732e2148 href="http://www.ncbi.nlm.nih.gov/pubmed/23773330">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2151 href="https://doi.org/10.1016/j.coviro.2013.04.007">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2154 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743920">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d31732e2163 class=n-a></a>McCormick JB, King IJ, Webb PA, <i> et al.</i>: Lassa fever. Effective therapy with ribavirin. <i>N Engl J Med.</i> 1986; <b>314</b>(1): 20–6. <a target=xrefwindow id=d31732e2174 href="http://www.ncbi.nlm.nih.gov/pubmed/3940312">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2177 href="https://doi.org/10.1056/NEJM198601023140104">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d31732e2186 class=n-a></a>McCormick JB, Webb PA, Krebs JW, <i> et al.</i>: A prospective study of the epidemiology and ecology of Lassa fever. <i>J Infect Dis.</i> 1987; <b>155</b>(3): 437–44. <a target=xrefwindow id=d31732e2197 href="http://www.ncbi.nlm.nih.gov/pubmed/3805771">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2200 href="https://doi.org/10.1093/infdis/155.3.437">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d31732e2209 class=n-a></a>Johnson KM, McCormick JB, Webb PA, <i> et al.</i>: Clinical virology of Lassa fever in hospitalized patients. <i>J Infect Dis.</i> 1987; <b>155</b>(3): 456–64. <a target=xrefwindow id=d31732e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/3805773">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2223 href="https://doi.org/10.1093/infdis/155.3.456">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d31732e2232 class=n-a></a>McCormick JB, Fisher-Hoch SP: Lassa fever. <i>Curr Top Microbiol Immunol.</i> 2002; <b>262</b>: 75–109. <a target=xrefwindow id=d31732e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/11987809">PubMed Abstract </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d31732e2249 class=n-a></a>Akpede GO, Asogun DA, Okogbenin SA, <i> et al.</i>: Lassa fever outbreaks in Nigeria. <i>Expert Rev Anti Infect Ther.</i> 2018; <b>16</b>(9): 663–666. <a target=xrefwindow id=d31732e2260 href="http://www.ncbi.nlm.nih.gov/pubmed/30111178">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2263 href="https://doi.org/10.1080/14787210.2018.1512856">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732338435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2273 class=n-a></a>Buba MI, Dalhat MM, Nguku PM, <i> et al.</i>: Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria. <i>Am J Public Health.</i> 2018; <b>108</b>(2): 262–264. <a target=xrefwindow id=d31732e2284 href="http://www.ncbi.nlm.nih.gov/pubmed/29267063">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2287 href="https://doi.org/10.2105/AJPH.2017.304186">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732338435">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d31732e2300 class=n-a></a>Roberts L: Nigeria hit by unprecedented Lassa fever outbreak. <i>Science.</i> 2018; <b>359</b>(6381): 1201–1202. <a target=xrefwindow id=d31732e2308 href="http://www.ncbi.nlm.nih.gov/pubmed/29590055">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2311 href="https://doi.org/10.1126/science.359.6381.1201">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d31732e2320 class=n-a></a>The Lancet Infectious Diseases: Lassa fever and global health security. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(4): 357. <a target=xrefwindow id=d31732e2328 href="http://www.ncbi.nlm.nih.gov/pubmed/29582756">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2331 href="https://doi.org/10.1016/S1473-3099(18)30179-8">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d31732e2340 class=n-a></a>WHO: Annual review of diseases prioritized under the Research and Development Blueprint. 2017; Accessed December 20. <a target=xrefwindow id=d31732e2342 href="https://www.who.int/blueprint/what/research-development/2017-Prioritization-Long-Report.pdf">Reference Source</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d31732e2351 class=n-a></a>WHO: Lassa Fever. 2018. <a target=xrefwindow id=d31732e2353 href="https://www.who.int/csr/don/20-april-2018-lassa-fever-nigeria/en/">Reference Source</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d31732e2362 class=n-a></a>WHO: Nigeria - Lassa Fever. DIsease Outbreak News June 28, 2017. 2017. <a target=xrefwindow id=d31732e2364 href="https://www.who.int/csr/don/28-june-2017-lassa-fever-nigeria/en/">Reference Source</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d31732e2374 class=n-a></a>Lukashevich I, Salvato M: Lassa Virus Genome. <i>Curr Genomics.</i> 2006; <b>7</b>(6): 351–79. <a target=xrefwindow id=d31732e2382 href="https://doi.org/10.2174/138920206778948673">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d31732e2391 class=n-a></a>Ehichioya DU, Hass M, Becker-Ziaja B, <i> et al.</i>: Current molecular epidemiology of Lassa virus in Nigeria. <i>J Clin Microbiol.</i> 2011; <b>49</b>(3): 1157–61. <a target=xrefwindow id=d31732e2402 href="http://www.ncbi.nlm.nih.gov/pubmed/21191050">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2405 href="https://doi.org/10.1128/JCM.01891-10">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3067713">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d31732e2418 class=n-a></a>Andersen KG, Shapiro BJ, Matranga CB, <i> et al.</i>: Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. <i>Cell.</i> 2015; <b>162</b>(4): 738–50. <a target=xrefwindow id=d31732e2429 href="http://www.ncbi.nlm.nih.gov/pubmed/26276630">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2432 href="https://doi.org/10.1016/j.cell.2015.07.020">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4537774">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d31732e2445 class=n-a></a>Manning JT, Forrester N, Paessler S: Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. <i>Front Microbiol.</i> 2015; <b>6</b>: 1037. <a target=xrefwindow id=d31732e2453 href="http://www.ncbi.nlm.nih.gov/pubmed/26483768">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2456 href="https://doi.org/10.3389/fmicb.2015.01037">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2459 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4589679">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d31732e2468 class=n-a></a>Bowen MD, Rollin PE, Ksiazek TG, <i> et al.</i>: Genetic diversity among Lassa virus strains. <i>J Virol.</i> 2000; <b>74</b>(15): 6992–7004. <a target=xrefwindow id=d31732e2479 href="http://www.ncbi.nlm.nih.gov/pubmed/10888638">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2482 href="https://doi.org/10.1128/JVI.74.15.6992-7004.2000">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2486 href="http://www.ncbi.nlm.nih.gov/pmc/articles/112216">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d31732e2495 class=n-a></a>Leski TA, Stockelman MG, Moses LM, <i> et al.</i>: Sequence variability and geographic distribution of Lassa virus, Sierra Leone. <i>Emerging Infect Dis.</i> 2015; <b>21</b>(4): 609–18. <a target=xrefwindow id=d31732e2506 href="http://www.ncbi.nlm.nih.gov/pubmed/25811712">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2509 href="https://doi.org/10.3201/eid2104.141469">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2513 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4378485">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d31732e2523 class=n-a></a>Günther S, Emmerich P, Laue T, <i> et al.</i>: Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. <i>Emerging Infect Dis.</i> 2000; <b>6</b>(5): 466–76. <a target=xrefwindow id=d31732e2534 href="http://www.ncbi.nlm.nih.gov/pubmed/10998376">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2537 href="https://doi.org/10.3201/eid0605.000504">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2541 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2627947">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732734780"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2550 class=n-a></a>Whitmer SLM, Strecker T, Cadar D, <i> et al.</i>: New Lineage of Lassa Virus, Togo, 2016. <i>Emerging Infect Dis.</i> 2018; <b>24</b>(3): 599–602. <a target=xrefwindow id=d31732e2561 href="http://www.ncbi.nlm.nih.gov/pubmed/29460758">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2564 href="https://doi.org/10.3201/eid2403.171905">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2568 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5823357">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732734780">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d31732e2581 class=n-a></a>Lukashevich IS: The search for animal models for Lassa fever vaccine development. <i>Expert Rev Vaccines.</i> 2013; <b>12</b>(1): 71–86. <a target=xrefwindow id=d31732e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/23256740">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2592 href="https://doi.org/10.1586/erv.12.139">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3564576">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d31732e2604 class=n-a></a>Jahrling PB, Smith S, Hesse RA, <i> et al.</i>: Pathogenesis of Lassa virus infection in guinea pigs. <i>Infect Immun.</i> 1982; <b>37</b>(2): 771–8. <a target=xrefwindow id=d31732e2615 href="http://www.ncbi.nlm.nih.gov/pubmed/6749685">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2618 href="http://www.ncbi.nlm.nih.gov/pmc/articles/347596">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d31732e2627 class=n-a></a>Carrion R Jr, Patterson JL, Johnson C, <i> et al.</i>: A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. <i>Vaccine.</i> 2007; <b>25</b>(20): 4093–102. <a target=xrefwindow id=d31732e2638 href="http://www.ncbi.nlm.nih.gov/pubmed/17360080">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2641 href="https://doi.org/10.1016/j.vaccine.2007.02.038">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2645 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1892204">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734888476"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2654 class=n-a></a>Bell TM, Shaia CI, Bearss JJ, <i> et al.</i>: Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus. <i>Vet Pathol.</i> 2016; <b>54</b>(3): 549–62. <a target=xrefwindow id=d31732e2665 href="http://www.ncbi.nlm.nih.gov/pubmed/28438110">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2668 href="https://doi.org/10.1177/0300985816677153">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734888476">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d31732e2682 class=n-a></a>Safronetz D, Mire C, Rosenke K, <i> et al.</i>: A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. <i>PLoS Negl Trop Dis.</i> 2015; <b>9</b>(4): e0003736. <a target=xrefwindow id=d31732e2693 href="http://www.ncbi.nlm.nih.gov/pubmed/25884628">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2696 href="https://doi.org/10.1371/journal.pntd.0003736">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2700 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4401668">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d31732e2709 class=n-a></a>Peters CJ, Jahrling PB, Liu CT, <i> et al.</i>: Experimental studies of arenaviral hemorrhagic fevers. <i>Curr Top Microbiol Immunol.</i> 1987; <b>134</b>: 5–68. <a target=xrefwindow id=d31732e2720 href="http://www.ncbi.nlm.nih.gov/pubmed/3034512">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2723 href="https://doi.org/10.1007/978-3-642-71726-0_2">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d31732e2732 class=n-a></a>Clegg JC, Lloyd G: Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. <i>Lancet.</i> 1987; <b>330</b>(8552): 186–8. <a target=xrefwindow id=d31732e2740 href="http://www.ncbi.nlm.nih.gov/pubmed/2885642">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2743 href="https://doi.org/10.1016/S0140-6736(87)90767-7">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d31732e2752 class=n-a></a>Jahrling PB, Frame JD, Smith SB, <i> et al.</i>: Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. <i>Trans R Soc Trop Med Hyg.</i> 1985; <b>79</b>(3): 374–9. <a target=xrefwindow id=d31732e2763 href="http://www.ncbi.nlm.nih.gov/pubmed/3898483">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2766 href="https://doi.org/10.1016/0035-9203(85)90386-4">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d31732e2775 class=n-a></a>Baize S, Marianneau P, Loth P, <i> et al.</i>: Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. <i>J Virol.</i> 2009; <b>83</b>(11): 5890–903. <a target=xrefwindow id=d31732e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/19297492">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2789 href="https://doi.org/10.1128/JVI.01948-08">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2793 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2681932">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d31732e2802 class=n-a></a>Hensley LE, Smith MA, Geisbert JB, <i> et al.</i>: Pathogenesis of lassa fever in cynomolgus macaques. <i>Virol J.</i> 2011; <b>8</b>: 205. <a target=xrefwindow id=d31732e2813 href="http://www.ncbi.nlm.nih.gov/pubmed/21548931">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2816 href="https://doi.org/10.1186/1743-422X-8-205">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3104370">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727234342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2830 class=n-a></a>Prescott JB, Marzi A, Safronetz D, <i> et al.</i>: Immunobiology of Ebola and Lassa virus infections. <i>Nat Rev Immunol.</i> 2017; <b>17</b>(3): 195–207. <a target=xrefwindow id=d31732e2841 href="http://www.ncbi.nlm.nih.gov/pubmed/28111475">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2844 href="https://doi.org/10.1038/nri.2016.138">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727234342">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d31732e2857 class=n-a></a>Safronetz D, Strong JE, Feldmann F, <i> et al.</i>: A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. <i>J Infect Dis.</i> 2013; <b>207</b>(8): 1316–27. <a target=xrefwindow id=d31732e2868 href="http://www.ncbi.nlm.nih.gov/pubmed/23303805">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2871 href="https://doi.org/10.1093/infdis/jit004">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2875 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3603532">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732824007"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e2884 class=n-a></a>Okokhere P, Colubri A, Azubike C, <i> et al.</i>: Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(6): 684–95. <a target=xrefwindow id=d31732e2895 href="http://www.ncbi.nlm.nih.gov/pubmed/29523497">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2898 href="https://doi.org/10.1016/S1473-3099(18)30121-X">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2902 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5984133">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732824007">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d31732e2915 class=n-a></a>Beier JI, Jokinen JD, Holz GE, <i> et al.</i>: Novel mechanism of arenavirus-induced liver pathology. <i>PLoS One.</i> 2015; <b>10</b>(3): e0122839. <a target=xrefwindow id=d31732e2926 href="http://www.ncbi.nlm.nih.gov/pubmed/25822203">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2929 href="https://doi.org/10.1371/journal.pone.0122839">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2933 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4378851">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d31732e2942 class=n-a></a>Keane E, Gilles HM: Lassa fever in Panguma Hospital, Sierra Leone, 1973-6. <i>Br Med J.</i> 1977; <b>1</b>(6073): 1399–402. <a target=xrefwindow id=d31732e2950 href="http://www.ncbi.nlm.nih.gov/pubmed/861652">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2953 href="https://doi.org/10.1136/bmj.1.6073.1399">Publisher Full Text </a> | <a target=xrefwindow id=d31732e2956 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1606930">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d31732e2965 class=n-a></a>McCormick JB, King IJ, Webb PA, <i> et al.</i>: A Case-Control Study of the Clinical Diagnosis and Course of Lassa Fever. <i>J Infect Dis.</i> 1987; <b>155</b>(3): 445–55. <a target=xrefwindow id=d31732e2976 href="http://www.ncbi.nlm.nih.gov/pubmed/3805772">PubMed Abstract </a> | <a target=xrefwindow id=d31732e2979 href="https://doi.org/10.1093/infdis/155.3.445">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d31732e2989 class=n-a></a>Frame JD: Clinical features of Lassa fever in Liberia. <i>Rev Infect Dis.</i> 1989; <b>11 Suppl 4</b>: S783–S789. <a target=xrefwindow id=d31732e2997 href="http://www.ncbi.nlm.nih.gov/pubmed/2749109">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3000 href="https://doi.org/10.1093/clinids/11.Supplement_4.S783">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d31732e3009 class=n-a></a>Mahanty S, Hutchinson K, Agarwal S, <i> et al.</i>: Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. <i>J Immunol.</i> 2003; <b>170</b>(6): 2797–801. <a target=xrefwindow id=d31732e3020 href="http://www.ncbi.nlm.nih.gov/pubmed/12626527">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3023 href="https://doi.org/10.4049/jimmunol.170.6.2797">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d31732e3032 class=n-a></a>McCormick JB, Walker DH, King IJ, <i> et al.</i>: Lassa virus hepatitis: a study of fatal Lassa fever in humans. <i>Am J Trop Med Hyg.</i> 1986; <b>35</b>(2): 401–7. <a target=xrefwindow id=d31732e3043 href="http://www.ncbi.nlm.nih.gov/pubmed/3953952">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3046 href="https://doi.org/10.4269/ajtmh.1986.35.401">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d31732e3055 class=n-a></a>Lukashevich IS, Tikhonov I, Rodas JD, <i> et al.</i>: Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. <i>J Virol.</i> 2003; <b>77</b>(3): 1727–37. <a target=xrefwindow id=d31732e3066 href="http://www.ncbi.nlm.nih.gov/pubmed/12525606">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3069 href="https://doi.org/10.1128/JVI.77.3.1727-1737.2003">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3073 href="http://www.ncbi.nlm.nih.gov/pmc/articles/140927">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d31732e3082 class=n-a></a>Isa SE, Shehu NY, Juryit RN, <i> et al.</i>: Epidemiological and clinical description of Lassa fever in Jos, Nigeria. <i>High Med Res J.</i> 2013; <b>13</b>(1): 3–7. <a target=xrefwindow id=d31732e3093 href="https://www.ajol.info/index.php/hmrj/article/view/113318">Reference Source</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d31732e3102 class=n-a></a>Shehu NY, Gomerep SS, Isa SE, <i> et al.</i>: Lassa Fever 2016 Outbreak in Plateau State, Nigeria-The Changing Epidemiology and Clinical Presentation. <i>Front Public Health.</i> 2018; <b>6</b>: 232. <a target=xrefwindow id=d31732e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/30211144">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3116 href="https://doi.org/10.3389/fpubh.2018.00232">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6123362">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d31732e3130 class=n-a></a>Carrion R Jr, Brasky K, Mansfield K, <i> et al.</i>: Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. <i>J Virol.</i> 2007; <b>81</b>(12): 6482–90. <a target=xrefwindow id=d31732e3141 href="http://www.ncbi.nlm.nih.gov/pubmed/17409137">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3144 href="https://doi.org/10.1128/JVI.02876-06">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1900113">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d31732e3157 class=n-a></a>Asogun DA, Adomeh DI, Ehimuan J, <i> et al.</i>: Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. <i>PLoS Negl Trop Dis.</i> 2012; <b>6</b>(9): e1839. <a target=xrefwindow id=d31732e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/23029594">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3171 href="https://doi.org/10.1371/journal.pntd.0001839">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3459880">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734243913"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3184 class=n-a></a>Siddle KJ, Eromon P, Barnes KG, <i> et al.</i>: Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. <i>N Engl J Med.</i> 2018; <b>379</b>(18): 1745–53. <a target=xrefwindow id=d31732e3195 href="http://www.ncbi.nlm.nih.gov/pubmed/30332564">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3198 href="https://doi.org/10.1056/NEJMoa1804498">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6181183">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734243913">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734558016"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3215 class=n-a></a>Oloniniyi OK, Unigwe US, Okada S, <i> et al.</i>: Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. <i>PLoS Negl Trop Dis.</i> 2018; <b>12</b>(11): e0006971. <a target=xrefwindow id=d31732e3226 href="http://www.ncbi.nlm.nih.gov/pubmed/30500827">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3229 href="https://doi.org/10.1371/journal.pntd.0006971">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3233 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6267959">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734558016">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d31732e3246 class=n-a></a>Ter Meulen J, Lukashevich I, Sidibe K, <i> et al.</i>: Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. <i>Am J Trop Med Hyg.</i> 1996; <b>55</b>(6): 661–6. <a target=xrefwindow id=d31732e3257 href="http://www.ncbi.nlm.nih.gov/pubmed/9025695">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3260 href="https://doi.org/10.4269/ajtmh.1996.55.661">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d31732e3269 class=n-a></a>Mateer EJ, Huang C, Shehu NY, <i> et al.</i>: Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. <i>PLoS Negl Trop Dis.</i> 2018; <b>12</b>(2): e0006187. <a target=xrefwindow id=d31732e3280 href="http://www.ncbi.nlm.nih.gov/pubmed/29470486">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3283 href="https://doi.org/10.1371/journal.pntd.0006187">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5823363">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d31732e3297 class=n-a></a>Yun NE, Ronca S, Tamura A, <i> et al.</i>: Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. <i>J Virol.</i> 2015; <b>90</b>(6): 2920–7. <a target=xrefwindow id=d31732e3308 href="http://www.ncbi.nlm.nih.gov/pubmed/26719273">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3311 href="https://doi.org/10.1128/JVI.02948-15">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3315 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4810655">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734324389"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3324 class=n-a></a>Cashman KA, Wilkinson ER, Zeng X, <i> et al.</i>: Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques. <i>mBio.</i> 2018; <b>9</b>(5): pii: e01896-18. <a target=xrefwindow id=d31732e3335 href="http://www.ncbi.nlm.nih.gov/pubmed/30377282">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3338 href="https://doi.org/10.1128/mBio.01896-18">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6212830">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734324389">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d31732e3355 class=n-a></a>Fisher-Hoch SP, Hutwagner L, Brown B, <i> et al.</i>: Effective Vaccine for Lassa Fever. <i>J Virol.</i> 2000; <b>74</b>(15): 6777–83. <a target=xrefwindow id=d31732e3366 href="http://www.ncbi.nlm.nih.gov/pubmed/10888616">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3369 href="https://doi.org/10.1128/JVI.74.15.6777-6783.2000">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3373 href="http://www.ncbi.nlm.nih.gov/pmc/articles/112194">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d31732e3382 class=n-a></a>Fisher-Hoch SP, McCormick JB: Lassa fever vaccine. <i>Expert Rev Vaccines.</i> 2014; <b>3</b>(2): 189–97. <a target=xrefwindow id=d31732e3390 href="http://www.ncbi.nlm.nih.gov/pubmed/15056044">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3393 href="https://doi.org/10.1586/14760584.3.2.189">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d31732e3402 class=n-a></a>Yun NE, Walker DH: Pathogenesis of Lassa fever. <i>Viruses.</i> 2012; <b>4</b>(10): 2031–48. <a target=xrefwindow id=d31732e3410 href="http://www.ncbi.nlm.nih.gov/pubmed/23202452">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3413 href="https://doi.org/10.3390/v4102031">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3416 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3497040">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732871810"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3425 class=n-a></a>Hallam HJ, Hallam S, Rodriguez SE, <i> et al.</i>: Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. <i>NPJ Vaccines.</i> 2018; <b>3</b>: 11. <a target=xrefwindow id=d31732e3436 href="http://www.ncbi.nlm.nih.gov/pubmed/29581897">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3439 href="https://doi.org/10.1038/s41541-018-0049-5">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5861057">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732871810">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730919539"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3457 class=n-a></a>McElroy AK, Akondy RS, Harmon JR, <i> et al.</i>: A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses. <i>J Infect Dis.</i> 2017; <b>215</b>(12): 1862–1872. <a target=xrefwindow id=d31732e3468 href="http://www.ncbi.nlm.nih.gov/pubmed/28863472">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3471 href="https://doi.org/10.1093/infdis/jix201">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3475 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5853890">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730919539">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d31732e3488 class=n-a></a>McCormick JB: Clinical, epidemiologic, and therapeutic aspects of Lassa fever. <i>Med Microbiol Immunol.</i> 1986; <b>175</b>(2–3): 153–5. <a target=xrefwindow id=d31732e3496 href="http://www.ncbi.nlm.nih.gov/pubmed/3724661">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3499 href="https://doi.org/10.1007/BF02122438">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d31732e3508 class=n-a></a>McCormick JB: Lassa fever. <i>Factors in Emergence and Control of Rodent-borne Viral Diseases</i> (Hantaviral and Arenal Diseases) J. F. Saluzzo, B. Dodet, eds Elsevier: 1999; 177–195.</span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d31732e3520 class=n-a></a>ter Meulen J, Badusche M, Kuhnt K, <i> et al.</i>: Characterization of human CD4<sup>+</sup> T-Cell clones recognizing conserved and variable epitopes of the lassa virus nucleoprotein. <i>J Virol.</i> 2000; <b>74</b>(5): 2186–92. <a target=xrefwindow id=d31732e3534 href="http://www.ncbi.nlm.nih.gov/pubmed/10666248">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3538 href="https://doi.org/10.1128/JVI.74.5.2186-2192.2000">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3541 href="http://www.ncbi.nlm.nih.gov/pmc/articles/111699">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d31732e3550 class=n-a></a>Meulen Jt, Badusche M, Satoguina J, <i> et al.</i>: Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. <i>Virology.</i> 2004; <b>321</b>(1): 134–43. <a target=xrefwindow id=d31732e3561 href="http://www.ncbi.nlm.nih.gov/pubmed/15033572">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3564 href="https://doi.org/10.1016/j.virol.2003.12.013">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726648514"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3573 class=n-a></a>Cross RW, Mire CE, Branco LM, <i> et al.</i>: Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. <i>Antiviral Res.</i> 2016; <b>133</b>: 218–22. <a target=xrefwindow id=d31732e3584 href="http://www.ncbi.nlm.nih.gov/pubmed/27531367">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3587 href="https://doi.org/10.1016/j.antiviral.2016.08.012">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3591 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5032844">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726648514">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726345269"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3605 class=n-a></a>Robinson JE, Hastie KM, Cross RW, <i> et al.</i>: Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. <i>Nat Commun.</i> 2016; <b>7</b>: 11544. <a target=xrefwindow id=d31732e3616 href="http://www.ncbi.nlm.nih.gov/pubmed/27161536">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3619 href="https://doi.org/10.1038/ncomms11544">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4866400">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726345269">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d31732e3636 class=n-a></a>Botten J, Alexander J, Pasquetto V, <i> et al.</i>: Identification of protective Lassa virus epitopes that are restricted by HLA-A2. <i>J Virol.</i> 2006; <b>80</b>(17): 8351–61. <a target=xrefwindow id=d31732e3647 href="http://www.ncbi.nlm.nih.gov/pubmed/16912286">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3650 href="https://doi.org/10.1128/JVI.00896-06">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3654 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1563871">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d31732e3663 class=n-a></a>Lukashevich IS: Generation of reassortants between African arenaviruses. <i>Virology.</i> 1992; <b>188</b>(2): 600–5. <a target=xrefwindow id=d31732e3671 href="http://www.ncbi.nlm.nih.gov/pubmed/1585636">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3674 href="https://doi.org/10.1016/0042-6822(92)90514-P">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d31732e3683 class=n-a></a>Lukashevich IS, Patterson J, Carrion R, <i> et al.</i>: A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. <i>J Virol.</i> 2005; <b>79</b>(22): 13934–42. <a target=xrefwindow id=d31732e3694 href="http://www.ncbi.nlm.nih.gov/pubmed/16254329">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3697 href="https://doi.org/10.1128/JVI.79.22.13934-13942.2005">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3701 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1280243">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d31732e3710 class=n-a></a>Lukashevich IS, Pushko P: Vaccine platforms to control Lassa fever. <i>Expert Rev Vaccines.</i> 2016; <b>15</b>(9): 1135–50. <a target=xrefwindow id=d31732e3718 href="http://www.ncbi.nlm.nih.gov/pubmed/27136941">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3721 href="https://doi.org/10.1080/14760584.2016.1184575">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d31732e3730 class=n-a></a>Schildknecht A, Welti S, Geuking MB, <i> et al.</i>: Absence of CTL responses to early viral antigens facilitates viral persistence. <i>J Immunol.</i> 2008; <b>180</b>(5): 3113–21. <a target=xrefwindow id=d31732e3741 href="http://www.ncbi.nlm.nih.gov/pubmed/18292534">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3744 href="https://doi.org/10.4049/jimmunol.180.5.3113">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d31732e3754 class=n-a></a>Emonet S, Lemasson JJ, Gonzalez JP, <i> et al.</i>: Phylogeny and evolution of old world arenaviruses. <i>Virology.</i> 2006; <b>350</b>(2): 251–7. <a target=xrefwindow id=d31732e3765 href="http://www.ncbi.nlm.nih.gov/pubmed/16494913">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3768 href="https://doi.org/10.1016/j.virol.2006.01.026">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d31732e3777 class=n-a></a>Zapata JC, Pauza CD, Djavani MM, <i> et al.</i>: Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. <i>Antiviral Res.</i> 2011; <b>92</b>(2): 125–38. <a target=xrefwindow id=d31732e3788 href="http://www.ncbi.nlm.nih.gov/pubmed/21820469">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3791 href="https://doi.org/10.1016/j.antiviral.2011.07.015">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3209703">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d31732e3804 class=n-a></a>Zapata JC, Poonia B, Bryant J, <i> et al.</i>: An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. <i>Virol J.</i> 2013; <b>10</b>: 52. <a target=xrefwindow id=d31732e3815 href="http://www.ncbi.nlm.nih.gov/pubmed/23402317">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3818 href="https://doi.org/10.1186/1743-422X-10-52">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3602176">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d31732e3831 class=n-a></a>Zapata JC, Medina-Moreno S, Guzmán-Cardozo C, <i> et al.</i>: Improving the Breadth of the Host's Immune Response to Lassa Virus. <i>Pathogens.</i> 2018; <b>7</b>(4): pii: E84. <a target=xrefwindow id=d31732e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/30373278">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3845 href="https://doi.org/10.3390/pathogens7040084">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6313495">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d31732e3858 class=n-a></a>WHO: WHO Target Product Profile for Lassa virus Vaccine. 2017. <a target=xrefwindow id=d31732e3860 href="https://www.who.int/blueprint/priority-diseases/key-action/LassaVirusVaccineTPP.PDF?ua=1">Reference Source</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d31732e3869 class=n-a></a>Auperin DD, Esposito JJ, Lange JV, <i> et al.</i>: Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. <i>Virus Res.</i> 1988; <b>9</b>(2–3): 233–48. <a target=xrefwindow id=d31732e3880 href="http://www.ncbi.nlm.nih.gov/pubmed/3354260">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3883 href="https://doi.org/10.1016/0168-1702(88)90033-0">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d31732e3893 class=n-a></a>Garbutt M, Liebscher R, Wahl-Jensen V, <i> et al.</i>: Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. <i>J Virol.</i> 2004; <b>78</b>(10): 5458–65. <a target=xrefwindow id=d31732e3904 href="http://www.ncbi.nlm.nih.gov/pubmed/15113924">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3907 href="https://doi.org/10.1128/JVI.78.10.5458-5465.2004">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/400370">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d31732e3920 class=n-a></a>Geisbert TW, Jones S, Fritz EA, <i> et al.</i>: Development of a new vaccine for the prevention of Lassa fever. <i>PLoS Med.</i> 2005; <b>2</b>(6): e183. <a target=xrefwindow id=d31732e3931 href="http://www.ncbi.nlm.nih.gov/pubmed/15971954">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3934 href="https://doi.org/10.1371/journal.pmed.0020183">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1160587">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d31732e3947 class=n-a></a>Kiley MP, Lange JV, Johnson KM: Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. <i>Lancet.</i> 1979; <b>2</b>(8145): 738. <a target=xrefwindow id=d31732e3955 href="http://www.ncbi.nlm.nih.gov/pubmed/90819">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3958 href="https://doi.org/10.1016/S0140-6736(79)90659-7">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732925589"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e3967 class=n-a></a>Carnec X, Mateo M, Page A, <i> et al.</i>: A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. <i>J Virol.</i> 2018; <b>92</b>(12): pii: e02230-17. <a target=xrefwindow id=d31732e3978 href="http://www.ncbi.nlm.nih.gov/pubmed/29593043">PubMed Abstract </a> | <a target=xrefwindow id=d31732e3981 href="https://doi.org/10.1128/JVI.02230-17">Publisher Full Text </a> | <a target=xrefwindow id=d31732e3985 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5974477">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732925589">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d31732e3998 class=n-a></a>Bredenbeek PJ, Molenkamp R, Spaan WJ, <i> et al.</i>: A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. <i>Virology.</i> 2006; <b>345</b>(2): 299–304. <a target=xrefwindow id=d31732e4009 href="http://www.ncbi.nlm.nih.gov/pubmed/16412488">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4012 href="https://doi.org/10.1016/j.virol.2005.12.001">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4016 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1388090">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d31732e4025 class=n-a></a>Jiang X, Dalebout TJ, Bredenbeek PJ, <i> et al.</i>: Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. <i>Vaccine.</i> 2011; <b>29</b>(6): 1248–57. <a target=xrefwindow id=d31732e4036 href="http://www.ncbi.nlm.nih.gov/pubmed/21145373">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4039 href="https://doi.org/10.1016/j.vaccine.2010.11.079">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3297484">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d31732e4053 class=n-a></a>Pushko P, Geisbert J, Parker M, <i> et al.</i>: Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. <i>J Virol.</i> 2001; <b>75</b>(23): 11677–85. <a target=xrefwindow id=d31732e4064 href="http://www.ncbi.nlm.nih.gov/pubmed/11689649">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4067 href="https://doi.org/10.1128/JVI.75.23.11677-11685.2001">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/114754">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d31732e4080 class=n-a></a>Wang M, Jokinen J, Tretyakova I, <i> et al.</i>: Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. <i>Vaccine.</i> 2018; <b>36</b>(5): 683–90. <a target=xrefwindow id=d31732e4091 href="http://www.ncbi.nlm.nih.gov/pubmed/29287681">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4094 href="https://doi.org/10.1016/j.vaccine.2017.12.046">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4098 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5806529">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d31732e4107 class=n-a></a>Cohen J: Unfilled Vials. <i>Science.</i> 2016; <b>351</b>(6268): 16–9. <a target=xrefwindow id=d31732e4115 href="http://www.ncbi.nlm.nih.gov/pubmed/26721985">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4118 href="https://doi.org/10.1126/science.351.6268.16">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d31732e4127 class=n-a></a>Lukashevich IS, Carrion R Jr, Salvato MS, <i> et al.</i>: Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. <i>Vaccine.</i> 2008; <b>26</b>(41): 5246–54. <a target=xrefwindow id=d31732e4138 href="http://www.ncbi.nlm.nih.gov/pubmed/18692539">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4141 href="https://doi.org/10.1016/j.vaccine.2008.07.057">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2582173">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d31732e4154 class=n-a></a>Zapata JC, Goicochea M, Nadai Y, <i> et al.</i>: Genetic variation <i>in vitro</i> and <i>in vivo</i> of an attenuated Lassa vaccine candidate. <i>J Virol.</i> 2014; <b>88</b>(6): 3058–66. <a target=xrefwindow id=d31732e4172 href="http://www.ncbi.nlm.nih.gov/pubmed/24335292">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4175 href="https://doi.org/10.1128/JVI.03035-13">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4178 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3957910">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d31732e4187 class=n-a></a>Carrion R Jr, Bredenbeek P, Jiang X, <i> et al.</i>: Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. <i>J Vaccines Vaccin.</i> 2012; <b>3</b>(7): pii: 1000160. <a target=xrefwindow id=d31732e4198 href="http://www.ncbi.nlm.nih.gov/pubmed/23420494">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4201 href="https://doi.org/10.4172/2157-7560.1000160">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3573532">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d31732e4215 class=n-a></a>Goicochea MA, Zapata JC, Bryant J, <i> et al.</i>: Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. <i>Vaccine.</i> 2012; <b>30</b>(8): 1445–52. <a target=xrefwindow id=d31732e4226 href="http://www.ncbi.nlm.nih.gov/pubmed/22234266">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4229 href="https://doi.org/10.1016/j.vaccine.2011.12.134">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4233 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3562134">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d31732e4242 class=n-a></a>Morrison HG, Bauer SP, Lange JV, <i> et al.</i>: Protection of guinea pigs from lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of lassa virus. <i>Virology.</i> 1989; <b>171</b>(1): 179–88. <a target=xrefwindow id=d31732e4253 href="http://www.ncbi.nlm.nih.gov/pubmed/2741340">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4256 href="https://doi.org/10.1016/0042-6822(89)90525-4">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732006764"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4265 class=n-a></a>Cashman KA, Wilkinson ER, Shaia CI, <i> et al.</i>: A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. <i>Hum Vaccin Immunother.</i> 2017; <b>13</b>(12): 2902–11. <a target=xrefwindow id=d31732e4276 href="http://www.ncbi.nlm.nih.gov/pubmed/29045192">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4279 href="https://doi.org/10.1080/21645515.2017.1356500">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4283 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5718832">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732006764">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d31732e4296 class=n-a></a>Iwasaki M, Cubitt B, Jokinen J, <i> et al.</i>: Use of recombinant ML29 platform to generate polyvalent live-attenuated vaccines against lassa fever and other infectious diseases. <i>The 66th Annual Meeting of Japanese Society for Virology</i>. 2018. <a target=xrefwindow id=d31732e4304 href="http://www.c-linkage.co.jp/jsv66/data/accepted_abstracts.pdf">Reference Source</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d31732e4313 class=n-a></a>Emonet SF, Garidou L, McGavern DB, <i> et al.</i>: Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(9): 3473–8. <a target=xrefwindow id=d31732e4324 href="http://www.ncbi.nlm.nih.gov/pubmed/19208813">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4327 href="https://doi.org/10.1073/pnas.0900088106">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4331 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2651270">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727629620"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4340 class=n-a></a>Plotkin SA: Vaccines for epidemic infections and the role of CEPI. <i>Hum Vaccin Immunother.</i> 2017; <b>13</b>(12): 2755–62. <a target=xrefwindow id=d31732e4348 href="http://www.ncbi.nlm.nih.gov/pubmed/28375764">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4351 href="https://doi.org/10.1080/21645515.2017.1306615">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4354 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5718831">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727629620">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725377821"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4368 class=n-a></a>Ramsauer K, Schwameis M, Firbas C, <i> et al.</i>: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. <i>Lancet Infect Dis.</i> 2015; <b>15</b>(5): 519–27. <a target=xrefwindow id=d31732e4379 href="http://www.ncbi.nlm.nih.gov/pubmed/25739878">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4382 href="https://doi.org/10.1016/S1473-3099(15)70043-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725377821">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d31732e4395 class=n-a></a>inovio: Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS. 2018. <a target=xrefwindow id=d31732e4397 href="https://globenewswire.com/news-release/2018/04/11/1468470/0/en/Inovio-Awarded-up-to-56-Million-from-CEPI-to-Advance-DNA-Vaccines-Against-Lassa-Fever-and-MERS.html">Reference Source</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d31732e4406 class=n-a></a>Lee J, Arun Kumar S, Jhan YY, <i> et al.</i>: Engineering DNA vaccines against infectious diseases. <i>Acta Biomater.</i> 2018; <b>80</b>: 31–47. <a target=xrefwindow id=d31732e4417 href="http://www.ncbi.nlm.nih.gov/pubmed/30172933">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4420 href="https://doi.org/10.1016/j.actbio.2018.08.033">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d31732e4429 class=n-a></a>Kelvey J: Work on DNA Vaccines Still Has a Way to Go. <i>Gen Eng &amp; Biotech News</i>. 2018. <a target=xrefwindow id=d31732e4434 href="https://www.genengnews.com/gen-exclusives/work-on-dna-vaccines-still-has-a-way-to-go/77901080/?utm_medium=newsletter&amp;utm_source=gen+daily+news+highlights&amp;utm_content=77901001&amp;utm_campaign=gen+daily+news+highlights_20180419&amp;ajs_trait_oebid=77909675b79130356b77901087s">Reference Source</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d31732e4443 class=n-a></a>Rodriguez-Carreno MP, Nelson MS, Botten J, <i> et al.</i>: Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. <i>Virology.</i> 2005; <b>335</b>(1): 87–98. <a target=xrefwindow id=d31732e4454 href="http://www.ncbi.nlm.nih.gov/pubmed/15823608">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4457 href="https://doi.org/10.1016/j.virol.2005.01.019">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d31732e4466 class=n-a></a>Henao-Restrepo AM, Camacho A, Longini IM, <i> et al.</i>: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). <i>Lancet.</i> 2017; <b>389</b>(10068): 505–18. <a target=xrefwindow id=d31732e4477 href="http://www.ncbi.nlm.nih.gov/pubmed/28017403">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4480 href="https://doi.org/10.1016/S0140-6736(16)32621-6">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5364328">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725702666"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4494 class=n-a></a>Henao-Restrepo AM, Longini IM, Egger M, <i> et al.</i>: Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. <i>Lancet.</i> 2015; <b>386</b>(9996): 857–66. <a target=xrefwindow id=d31732e4505 href="http://www.ncbi.nlm.nih.gov/pubmed/26248676">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4508 href="https://doi.org/10.1016/S0140-6736(15)61117-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725702666">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d31732e4521 class=n-a></a>Metzger WG, Vivas-Martínez S: Questionable efficacy of the rVSV-ZEBOV Ebola vaccine. <i>Lancet.</i> 2018; <b>391</b>(10125): 1021. <a target=xrefwindow id=d31732e4529 href="http://www.ncbi.nlm.nih.gov/pubmed/29565013">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4532 href="https://doi.org/10.1016/S0140-6736(18)30560-9">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725416094"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4541 class=n-a></a>Agnandji ST, Huttner A, Zinser ME, <i> et al.</i>: Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>N Engl J Med.</i> 2016; <b>374</b>(17): 1647–60. <a target=xrefwindow id=d31732e4552 href="http://www.ncbi.nlm.nih.gov/pubmed/25830326">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4555 href="https://doi.org/10.1056/NEJMoa1502924">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4559 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5490784">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725416094">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727504008"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4572 class=n-a></a>Huttner A, Combescure C, Grillet S, <i> et al.</i>: A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. <i>Sci Transl Med.</i> 2017; <b>9</b>(385): pii: eaaj1701. <a target=xrefwindow id=d31732e4583 href="http://www.ncbi.nlm.nih.gov/pubmed/28404856">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4586 href="https://doi.org/10.1126/scitranslmed.aaj1701">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727504008">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d31732e4599 class=n-a></a>Meyer M, Malherbe DC, Bukreyev A: Can Ebola Virus Vaccines Have Universal Immune Correlates of protection? <i>Trends Microbiol.</i> 2019; <b>27</b>(1): 8–16. <a target=xrefwindow id=d31732e4607 href="http://www.ncbi.nlm.nih.gov/pubmed/30201511">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4610 href="https://doi.org/10.1016/j.tim.2018.08.008">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4613 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6309495">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d31732e4622 class=n-a></a>Clarke DK, Nasar F, Chong S, <i> et al.</i>: Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. <i>J Virol.</i> 2014; <b>88</b>(12): 6690–701. <a target=xrefwindow id=d31732e4633 href="http://www.ncbi.nlm.nih.gov/pubmed/24696472">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4636 href="https://doi.org/10.1128/JVI.03441-13">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4640 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4054374">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d31732e4650 class=n-a></a>Matassov D, Marzi A, Latham T, <i> et al.</i>: Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. <i>J Infect Dis.</i> 2015; <b>212 Suppl 2</b>: S443–51. <a target=xrefwindow id=d31732e4661 href="http://www.ncbi.nlm.nih.gov/pubmed/26109675">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4664 href="https://doi.org/10.1093/infdis/jiv316">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4668 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4564554">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d31732e4677 class=n-a></a>Mire CE, Matassov D, Geisbert JB, <i> et al.</i>: Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. <i>Nature.</i> 2015; <b>520</b>(7549): 688–91. <a target=xrefwindow id=d31732e4688 href="http://www.ncbi.nlm.nih.gov/pubmed/25853476">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4691 href="https://doi.org/10.1038/nature14428">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4695 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4629916">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732122440"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d31732e4704 class=n-a></a>Matassov D, Mire CE, Latham T, <i> et al.</i>: Single Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. <i>J Virol.</i> 2018; <b>92</b>(3): e01190–17. <a target=xrefwindow id=d31732e4715 href="http://www.ncbi.nlm.nih.gov/pubmed/29142131">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4718 href="https://doi.org/10.1128/JVI.01190-17">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5774882">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732122440">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d31732e4735 class=n-a></a>CEPI: CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines. the Coalition for Epidemic Preparedness Innovations Sept 27. 2018. </span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d31732e4744 class=n-a></a>Russier M, Pannetier D, Baize S: Immune responses and Lassa virus infection. <i>Viruses.</i> 2012; <b>4</b>(11): 2766–85. <a target=xrefwindow id=d31732e4752 href="http://www.ncbi.nlm.nih.gov/pubmed/23202504">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4755 href="https://doi.org/10.3390/v4112766">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4758 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3509672">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d31732e4767 class=n-a></a>Ambrosio A, Saavedra M, Mariani M, <i> et al.</i>: Argentine hemorrhagic fever vaccines. <i>Hum Vaccin.</i> 2011; <b>7</b>(6): 694–700. <a target=xrefwindow id=d31732e4778 href="http://www.ncbi.nlm.nih.gov/pubmed/21451263">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4781 href="https://doi.org/10.4161/hv.7.6.15198">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d31732e4791 class=n-a></a>Khan SH, Goba A, Chu M, <i> et al.</i>: New opportunities for field research on the pathogenesis and treatment of Lassa fever. <i>Antiviral Res.</i> 2008; <b>78</b>(1): 103–15. <a target=xrefwindow id=d31732e4802 href="http://www.ncbi.nlm.nih.gov/pubmed/18241935">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4805 href="https://doi.org/10.1016/j.antiviral.2007.11.003">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d31732e4814 class=n-a></a>Yozwiak NL, Happi CT, Grant DS, <i> et al.</i>: Roots, Not Parachutes: Research Collaborations Combat Outbreaks. <i>Cell.</i> 2016; <b>166</b>(1): 5–8. <a target=xrefwindow id=d31732e4825 href="http://www.ncbi.nlm.nih.gov/pubmed/27368093">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4828 href="https://doi.org/10.1016/j.cell.2016.06.029">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5210219">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d31732e4841 class=n-a></a>Abreu-Mota T, Hagen KR, Cooper K, <i> et al.</i>: Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. <i>Nat Commun.</i> 2018; <b>9</b>(1): 4223. <a target=xrefwindow id=d31732e4852 href="http://www.ncbi.nlm.nih.gov/pubmed/30310067">PubMed Abstract </a> | <a target=xrefwindow id=d31732e4855 href="https://doi.org/10.1038/s41467-018-06741-w">Publisher Full Text </a> | <a target=xrefwindow id=d31732e4859 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6181965">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-134.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-134.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 40292, USA<br/> <sup>2</sup> Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA<br/> <sup>3</sup> Department of Immunology and Microbiology IMM-6, The Scripps Research Institute, La Jolla, CA, 92037, USA<br/> <p> <div class=margin-bottom> Igor S. Lukashevich <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Slobodan Paessler <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Juan Carlos de la Torre <br/> <span>Roles: </span> Data Curation, Visualization, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-134/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 31 Jan 2019, 8:134 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.16989.1">https://doi.org/10.12688/f1000research.16989.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Lukashevich IS <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=18574 data-id=16989 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16989.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-134/v1/pdf?article_uuid=02320d34-25fb-4399-bb6d-79bf4df0585b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.16989.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lukashevich IS, Paessler S and de la Torre JC. Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):134 (<a href="https://doi.org/10.12688/f1000research.16989.1" target=_blank>https://doi.org/10.12688/f1000research.16989.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=16989 id=mobile-track-article-signin-16989 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16989?target=/articles/8-134.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18574 /> <input name=articleId type=hidden value=16989 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Hinh Ly</strong>, University of Minnesota - Twin Cities, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>George O Akpede</strong>, Departments of Paediatrics, Irrua Specialist Teaching Hospital, Nigeria; Ambrose Alli University, Nigeria </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Gabriele Neumann</strong>, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-134.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-134.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44951-43437></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44952-43438></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44953-43436></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-134/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>31 Jan 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Hinh Ly</strong>, University of Minnesota - Twin Cities, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>George O Akpede</strong>, Departments of Paediatrics, Irrua Specialist Teaching Hospital, Nigeria; Ambrose Alli University, Nigeria </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Gabriele Neumann</strong>, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-134.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-134/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Lassa virus diversity and feasibility for...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-134/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-134/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-134/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lukashevich IS et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-134/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-134",
            templates : {
                twitter : "Lassa virus diversity and feasibility for universal prophylactic.... Lukashevich IS et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-134/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Lassa virus diversity and feasibility for universal prophylactic vaccine", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Lassa virus diversity and feasibility for universal prophylactic vaccine", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/16989/18574")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "18574");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "43436": 0,
                           "43437": 0,
                           "43438": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "92fb6f13-cbf2-418e-b3de-589d9ba25414";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-134.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-134.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-134.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-134.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-134.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>